John Martin Overview

  • Investor Type
  • Angel

  • Investments
  • 4

  • Exits
  • 3

Exits

John Martin General Information

Description

Dr. John Martin served as the Chairman at Arresto BioSciences. He served as the Chairman and Executive Chairman and Director at Gilead Sciences. He served as President and Chief Executive Officer from 1996 through May 2008. Prior to joining Gilead, Dr. Martin held several leadership positions at Bristol-Myers Squibb and Syntex Corporation. Dr. Martin is a member of the Board of Directors of the California Healthcare Institute. He also serves on the University of Southern California Board of Trustees. Dr. Martin previously served as President of the International Society for Antiviral Research, Chairman of the Board of Directors of BayBio and Chairman of the Board of Directors of the California Healthcare Institute. He served on the National Institute of Allergy & Infectious Diseases Council, the Board of Directors of the Biotechnology Industry Organization, the Board of Trustees of the University of Chicago, the Board of Trustees of Golden Gate University and the External Scientific Advisory Board of the University of California School of Global Health. Additionally, Dr. Martin served on the Centers for Disease Control/Health Resources and Services Administration's Advisory Committee on HIV and STD Prevention and Treatment and was a member of the Presidential Advisory Council on HIV/AIDS. Dr. Martin holds a Ph.D. in organic chemistry from the University of Chicago and an MBA in marketing from Golden Gate University. He has received the Isbell Award from the American Chemical Society and the Gertrude B. Elion Award for Scientific Excellence from the International Society for Antiviral Research. In 2008, Dr. Martin was inducted into the National Academy of Engineering of the National Academies. He serves as a Board Member at Kronos Bio. He serves as Board Member at Sarepta Therapeutics.

Business Details

Primary Investor Type
Angel (individual)

John Martin Investments (4)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
School Day 12-May-2020 Seed Round 00.00 Education and Training Services (B2B) Generating Revenue 0000 000000 00.0
Kronos Bio 18-Jul-2019 00000 00000 00000 Biotechnology Generating Revenue/Not Profitable 0000 000000 00.0
Kronos Bio 23-May-2018 Seed Round 0000 Biotechnology Generating Revenue/Not Profitable 0000 000000 00.0
Bluesmart 01-Sep-2014 Seed Round 00000 Electronics (B2C) Bankruptcy: Liquidation

John Martin Exits (3)

Company Name Exit Date Exit Type Exit Size
School Day 09-May-2023 Merger/Acquisition
Kronos Bio 09-Oct-2020 000 00000
Bluesmart 01-May-2018 0000000000: 000000

John Martin Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

John Martin Team (1)

Name Title Deals Funds Boards Office
John Martin Ph.D Angel Investor 0 Palo Alto, CA

John Martin Co-Investors (2)

Name With Exits Lead Partner Series Industry
Lifeline Ventures 1 0 0 Series chart Industry bar
Sparkmind.vc 0 0 0 Series chart Industry bar

John Martin FAQs

  • Who is John Martin?

    John Martin is an angel Investor who has made 4 investments.

  • What kind of investor is John Martin?

    John Martin is an angel investor.

  • What does John Martin do?

    As an angel investor, John Martin invests personal money into promising companies, typically in exchange for equity.

  • What has John Martin invested in?

    John Martin has made numerous investments in companies like School Day, Kronos Bio, and Bluesmart within the Education and Training Services (B2B), Biotechnology, and Electronics (B2C) industries.

  • What has John Martin invested in recently?

    John Martin's latest investment was on 12-May-2020 in School Day, a company within the Education and Training Services (B2B) industry.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »